{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T11:55:57Z","timestamp":1785412557425,"version":"3.56.0"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2018,9,5]],"date-time":"2018-09-05T00:00:00Z","timestamp":1536105600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Sanofi China Investment\u00a0Company (CN)"},{"DOI":"10.13039\/100011421","name":"Sanofi China Investment\u00a0Company","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100011421","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Psychiatry"],"published-print":{"date-parts":[[2018,12]]},"DOI":"10.1186\/s12888-018-1867-8","type":"journal-article","created":{"date-parts":[[2018,9,5]],"date-time":"2018-09-05T09:32:29Z","timestamp":1536139949000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["Comparative efficacy and safety between amisulpride and olanzapine in schizophrenia treatment and a cost analysis in China: a systematic review, meta-analysis, and cost-minimization analysis"],"prefix":"10.1186","volume":"18","author":[{"given":"Peng","family":"Men","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhanmiao","family":"Yi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chaoyun","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuli","family":"Qu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tengbin","family":"Xiong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suodi","family":"Zhai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,9,5]]},"reference":[{"key":"1867_CR1","unstructured":"Schizophrenia overview. \n                    https:\/\/www.nimh.nih.gov\/health\/topics\/schizophrenia\/index.shtml\n                    \n                  . Accessed 26 Apr 2018."},{"key":"1867_CR2","doi-asserted-by":"publisher","first-page":"1545","DOI":"10.1016\/S0140-6736(16)31678-6","volume":"388","author":"GBD 2015 Disease and Injury Incidence and Prevalence Collaborators","year":"2016","unstructured":"GBD 2015 Disease and Injury Incidence and Prevalence Collaborators. Global, regional, and national incidence, prevalence, and years lived with disability for 310 diseases and injuries, 1990-2015: a systematic analysis for the global burden of disease study 2015. Lancet. 2016;388:1545\u2013602. \n                    https:\/\/doi.org\/10.1016\/S0140-6736(16)31678-6\n                    \n                  . PMID: 27733282","journal-title":"Lancet"},{"key":"1867_CR3","doi-asserted-by":"publisher","first-page":"010410","DOI":"10.7189\/jogh.05.010412","volume":"5","author":"KY Chan","year":"2015","unstructured":"Chan KY, Zhao F-F, Meng S, Demaio AR, Reed C, Theodoratou E, et al. Prevalence of schizophrenia in China between 1990 and 2010. J Glob Health. 2015;5:010410. \n                    https:\/\/doi.org\/10.7189\/jogh.05.010410\n                    \n                  . PMID: 26649171","journal-title":"J Glob Health"},{"key":"1867_CR4","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1111\/acps.12296","volume":"130","author":"J Long","year":"2014","unstructured":"Long J, Huang G, Liang W, Liang B, Chen Q, Xie J, et al. The prevalence of schizophrenia in mainland China: evidence from epidemiological surveys. Acta Psychiatr Scand. 2014;130:244\u201356. \n                    https:\/\/doi.org\/10.1111\/acps.12296\n                    \n                  . PMID: 24916190","journal-title":"Acta Psychiatr Scand"},{"key":"1867_CR5","doi-asserted-by":"publisher","first-page":"407","DOI":"10.2147\/CEOR.S44325","volume":"5","author":"W Montgomery","year":"2013","unstructured":"Montgomery W, Liu L, Stensland MD, Xue HB, Treuer T, Ascher-Svanum H. The personal, societal, and economic burden of schizophrenia in the People\u2019s Republic of China: implications for antipsychotic therapy. Clinicoecon Outcomes Res. 2013;5:407\u201318. \n                    https:\/\/doi.org\/10.2147\/CEOR.S44325\n                    \n                  . PMID: 23983478","journal-title":"Clinicoecon Outcomes Res"},{"key":"1867_CR6","doi-asserted-by":"publisher","first-page":"943","DOI":"10.1185\/03007991003658956","volume":"26","author":"D Nicholl","year":"2010","unstructured":"Nicholl D, Akhras K, Diels J. Burden of schizophrenia in recently diagnosed patients: healthcare utilisation and cost perspective. Curr Med Res Opin. 2010;26:943\u201355.","journal-title":"Curr Med Res Opin"},{"key":"1867_CR7","doi-asserted-by":"publisher","unstructured":"Chong HY, Teoh SL, DB-C W, Kotirum S, Chiou C-F, Chaiyakunapruk N. Global economic burden of schizophrenia: a systematic review. Neuropsychiatr Dis Treat. 2016; \n                    https:\/\/doi.org\/10.2147\/NDT.S96649\n                    \n                  .","DOI":"10.2147\/NDT.S96649"},{"key":"1867_CR8","doi-asserted-by":"publisher","first-page":"983","DOI":"10.2147\/NDT.S76231","volume":"11","author":"J Wu","year":"2015","unstructured":"Wu J, He X, Liu L, Ye W, Montgomery W, Xue H, et al. Health care resource use and direct medical costs for patients with schizophrenia in Tianjin, People\u2019s Republic of China. Neuropsychiatr Dis Treat. 2015;11:983\u201390. \n                    https:\/\/doi.org\/10.2147\/NDT.S76231\n                    \n                  . PMID: 25897235","journal-title":"Neuropsychiatr Dis Treat"},{"key":"1867_CR9","volume-title":"Chinese guidelines for the prevention and treatment of schizophrenia (version 2)","author":"J Zhao","year":"2015","unstructured":"Zhao J, Shi S. Chinese guidelines for the prevention and treatment of schizophrenia (version 2). 2015."},{"key":"1867_CR10","volume-title":"Investigation Report on China\u2019s Olanzapine Market 2015\u20132019","author":"Research and Markets","year":"2015","unstructured":"Research and Markets. Investigation Report on China\u2019s Olanzapine Market 2015\u20132019. 2015. \n                    https:\/\/www.prnewswire.com\/news-releases\/investigation-report-on-chinas-olanzapine-market-2015-2019-300125449.html\n                    \n                  . Accessed 26 Apr 2018."},{"key":"1867_CR11","doi-asserted-by":"publisher","first-page":"CD006624","DOI":"10.1002\/14651858.CD006624.pub2","volume":"1","author":"K Komossa","year":"2010","unstructured":"Komossa K, Rummel-Kluge C, Hunger H, Schmid F, Schwarz S, Silveira da Mota Neto JI, et al. Amisulpride versus other atypical antipsychotics for schizophrenia. Cochrane Database Syst Rev. 2010;1:CD006624. \n                    https:\/\/doi.org\/10.1002\/14651858.CD006624.pub2\n                    \n                  . PMID: 20091599","journal-title":"Cochrane Database Syst Rev"},{"key":"1867_CR12","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1097\/YIC.0000000000000111","volume":"31","author":"L Lin","year":"2016","unstructured":"Lin L, Zhao YJ, Zhou HJ, Khoo AL, Teng M, Soh LB, et al. Comparative cost-effectiveness of 11 oral antipsychotics for relapse prevention in schizophrenia within Singapore using effectiveness estimates from a network meta-analysis. Int Clin Psychopharmacol. 2016;31:84\u201392. \n                    https:\/\/doi.org\/10.1097\/YIC.0000000000000111\n                    \n                  . PMID: 26619182","journal-title":"Int Clin Psychopharmacol"},{"key":"1867_CR13","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1186\/2191-1991-2-8","volume":"2","author":"AJ Garc\u00eda-Ruiz","year":"2012","unstructured":"Garc\u00eda-Ruiz AJ, P\u00e9rez-Costillas L, Montesinos AC, Alcalde J, Oyag\u00fcez I, Casado MA. Cost-effectiveness analysis of antipsychotics in reducing schizophrenia relapses. Health Econ Rev. 2012;2:8. \n                    https:\/\/doi.org\/10.1186\/2191-1991-2-8\n                    \n                  . PMID: 22828390","journal-title":"Health Econ Rev"},{"key":"1867_CR14","doi-asserted-by":"publisher","first-page":"1979","DOI":"10.1111\/j.1742-1241.2007.01431.x","volume":"61","author":"M Obradovic","year":"2007","unstructured":"Obradovic M, Mrhar A, Kos M. Cost-effectiveness of antipsychotics for outpatients with chronic schizophrenia. Int J Clin Pract. 2007;61:1979\u201388. \n                    https:\/\/doi.org\/10.1111\/j.1742-1241.2007.01431.x\n                    \n                  .","journal-title":"Int J Clin Pract"},{"key":"1867_CR15","unstructured":"Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from: \n                    http:\/\/handbook.cochrane.org\n                    \n                  . Accessed 26 Apr 2018."},{"key":"1867_CR16","unstructured":"The guidelines manual | Guidance and guidelines | NICE. \n                    https:\/\/www.nice.org.uk\/process\/pmg6\/chapter\/introduction\n                    \n                  . Accessed 26 Apr 2018."},{"key":"1867_CR17","doi-asserted-by":"publisher","first-page":"d5928","DOI":"10.1136\/bmj.d5928","volume":"343","author":"JPT Higgins","year":"2011","unstructured":"Higgins JPT, Altman DG, G\u00f8tzsche PC, J\u00fcni P, Moher D, Oxman AD, et al. The Cochrane Collaboration\u2019s tool for assessing risk of bias in randomised trials. BMJ. 2011;343:d5928. PMID: 22008217","journal-title":"BMJ"},{"key":"1867_CR18","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1111\/j.1600-0447.2006.00887.x","volume":"114","author":"Y Lecrubier","year":"2006","unstructured":"Lecrubier Y, Quintin P, Bouhassira M, Perrin E, Lancrenon S. The treatment of negative symptoms and deficit states of chronic schizophrenia: olanzapine compared to amisulpride and placebo in a 6-month double-blind controlled clinical trial. Acta Psychiatr Scand. 2006;114:319\u201327. \n                    https:\/\/doi.org\/10.1111\/j.1600-0447.2006.00887.x\n                    \n                  . PMID: 17022791","journal-title":"Acta Psychiatr Scand"},{"key":"1867_CR19","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1111\/j.1365-2125.2010.03783.x","volume":"71","author":"SK Praharaj","year":"2011","unstructured":"Praharaj SK, Jana AK, Goyal N, Sinha VK. Metformin for olanzapine-induced weight gain: a systematic review and meta-analysis. Br J Clin Pharmacol. 2011;71:377\u201382. \n                    https:\/\/doi.org\/10.1111\/j.1365-2125.2010.03783.x\n                    \n                  . PMID: 21284696","journal-title":"Br J Clin Pharmacol"},{"key":"1867_CR20","doi-asserted-by":"publisher","first-page":"237","DOI":"10.3109\/00048670903487134","volume":"44","author":"S Bhowmick","year":"2010","unstructured":"Bhowmick S, Hazra A, Ghosh M. Amisulpride versus olanzapine in the treatment of schizophrenia in Indian patients: randomized controlled trial. Aust N Z J Psychiatry. 2010;44:237\u201342. \n                    https:\/\/doi.org\/10.3109\/00048670903487134\n                    \n                  . PMID: 20050717","journal-title":"Aust N Z J Psychiatry"},{"key":"1867_CR21","first-page":"197","volume":"25","author":"W Chu","year":"2015","unstructured":"Chu W, Chen Y, Zhao Y, Zhao B, Xu Z, Qiu R, et al. A comparison of six kinds of antipsychotic drugs\u2032effects on the cognitive function in patients with first episode schizophrenia. J Clin Psychiatry. 2015;25:197\u20139. \n                    https:\/\/bit.ly\/2KdKgFX\n                    \n                  . Accessed 26 Apr 2018","journal-title":"J Clin Psychiatry"},{"key":"1867_CR22","doi-asserted-by":"publisher","first-page":"284","DOI":"10.3969\/j.issn.1009-6574.2012.03.022.","volume":"12","author":"W Guo","year":"2012","unstructured":"Guo W, Xu H, Zhang X. A randomized and comparative study of amisulpride and olanzapine in treatment of schizophrenia. J Neurosci Ment Health. 2012;12:284\u20136. \n                    https:\/\/doi.org\/10.3969\/j.issn.1009-6574.2012.03.022.","journal-title":"J Neurosci Ment Health"},{"key":"1867_CR23","doi-asserted-by":"publisher","first-page":"1085","DOI":"10.1016\/S0140-6736(08)60486-9","volume":"371","author":"RS Kahn","year":"2008","unstructured":"Kahn RS, Fleischhacker WW, Boter H, Davidson M, Vergouwe Y, Keet IPM, et al. Effectiveness of antipsychotic drugs in first-episode schizophrenia and schizophreniform disorder: an open randomised clinical trial. Lancet. 2008;371:1085\u201397. \n                    https:\/\/doi.org\/10.1016\/S0140-6736(08)60486-9\n                    \n                  . PMID: 18374841","journal-title":"Lancet"},{"key":"1867_CR24","doi-asserted-by":"publisher","first-page":"34","DOI":"10.3969\/j.issn.1672-187X.2014.06.014-0034-03","volume":"20","author":"Y Kong","year":"2014","unstructured":"Kong Y, Song Y. A control study of amisulpride vs.olanzapine in the treatment of first-episode schizophrenia. J Cli Psychosom Dis. 2014;20:34\u201335,40. \n                    https:\/\/doi.org\/10.3969\/j.issn.1672-187X.2014.06.014-0034-03\n                    \n                  .","journal-title":"J Cli Psychosom Dis"},{"key":"1867_CR25","first-page":"14","volume":"42","author":"B Li","year":"2015","unstructured":"Li B, Chi Z, Chen B, Yan C. Effects of amisulpride, paliperidone extendedrelease tablets, olanzapine on cognitive and memory function of patients with first-episode schizophrenia and without medication. J Inte Tional Psychiatry. 2015;42:14\u20137. \n                    https:\/\/bit.ly\/2JrAMWn\n                    \n                  . Accessed 26 Apr 2018.","journal-title":"J Inte Tional Psychiatry"},{"key":"1867_CR26","unstructured":"Li F, Zheng X, Feng W. A control study on amisulpride and olanzapine in first episode patients with schizophrenia. 2014;24:121\u20132. \n                    https:\/\/bit.ly\/2FeQDFm\n                    \n                  . Accessed 26 Apr 2018."},{"key":"1867_CR27","doi-asserted-by":"publisher","first-page":"130","DOI":"10.11851\/j.issn.1673-1557.2015.02.018.","volume":"41","author":"H Lin","year":"2015","unstructured":"Lin H, Miao H. Clinical observation of amoxicillin and olanzapine in the treatment of acute schizophrenia. J Mod Clin Med. 2015;41:130\u20131. \n                    https:\/\/doi.org\/10.11851\/j.issn.1673-1557.2015.02.018.","journal-title":"J Mod Clin Med"},{"key":"1867_CR28","doi-asserted-by":"publisher","unstructured":"Liu X, Jin S, Li W. A control study of amisulpride vs olanzapine in the treatment of female schizophrenia. J Clin Psychosom Dis. 2015;21 \n                    https:\/\/doi.org\/10.3969\/j.issn.1672-187X.2015.02.012-0035-03\n                    \n                  .","DOI":"10.3969\/j.issn.1672-187X.2015.02.012-0035-03"},{"key":"1867_CR29","doi-asserted-by":"publisher","first-page":"499","DOI":"10.13342\/j.cnki.cjhp.2014.04.009.","volume":"22","author":"Z Lv","year":"2014","unstructured":"Lv Z, Zhou Z, Zhang Y. The treatment of female schizophrenia using Amisulpride and olanzapine. China J Health Psychol. 2014;22:499\u2013501. \n                    https:\/\/doi.org\/10.13342\/j.cnki.cjhp.2014.04.009.","journal-title":"China J Health Psychol"},{"key":"1867_CR30","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1097\/00004850-200403000-00002","volume":"19","author":"A Mortimer","year":"2004","unstructured":"Mortimer A, Martin S, L\u00f4o H, Peuskens J, SOLIANOL Sudy Group. A double-blind, randomized comparative trial of amisulpride versus olanzapine for 6 months in the treatment of schizophrenia. Int Clin Psychopharmacol. 2004;19:63\u20139. PMID: 15076013","journal-title":"Int Clin Psychopharmacol"},{"key":"1867_CR31","doi-asserted-by":"publisher","first-page":"703751","DOI":"10.5402\/2012\/703751","volume":"2012","author":"GR Pawar","year":"2012","unstructured":"Pawar GR, Phadnis P, Paliwal A. Evaluation of efficacy, safety, and cognitive profile of amisulpride per se and its comparison with olanzapine in newly diagnosed schizophrenic patients in an 8-week, double-blind, single-centre, prospective clinical trial. ISRN Psychiatry. 2012;2012:703751. \n                    https:\/\/doi.org\/10.5402\/2012\/703751\n                    \n                  . PMID: 23738210","journal-title":"ISRN Psychiatry"},{"key":"1867_CR32","doi-asserted-by":"publisher","first-page":"292","DOI":"10.16386\/j.cjpccd.issn.1004-6194.2013.03.048","volume":"21","author":"X Sun","year":"2013","unstructured":"Sun X, Yang J. The curative effects of amisulpride and olanzapine on acute schizophrenia. Chin J Prev Contr Chron Dis. 2013;21:292\u20133. 296. \n                    https:\/\/doi.org\/10.16386\/j.cjpccd.issn.1004-6194.2013.03.048\n                    \n                  .","journal-title":"Chin J Prev Contr Chron Dis"},{"key":"1867_CR33","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1016\/j.eurpsy.2006.09.003","volume":"21","author":"J-M Vanelle","year":"2006","unstructured":"Vanelle J-M, Douki S. A double-blind randomised comparative trial of amisulpride versus olanzapine for 2 months in the treatment of subjects with schizophrenia and comorbid depression. Eur Psychiatry. 2006;21:523\u201330. \n                    https:\/\/doi.org\/10.1016\/j.eurpsy.2006.09.003\n                    \n                  . PMID: 17113759","journal-title":"Eur Psychiatry"},{"key":"1867_CR34","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1038\/sj.npp.1300626","volume":"30","author":"M Wagner","year":"2005","unstructured":"Wagner M, Quednow BB, Westheide J, Schlaepfer TE, Maier W, K\u00fchn K-U. Cognitive improvement in schizophrenic patients does not require a serotonergic mechanism: randomized controlled trial of olanzapine vs amisulpride. Neuropsychopharmacology. 2005;30:381\u201390. \n                    https:\/\/doi.org\/10.1038\/sj.npp.1300626\n                    \n                  . PMID: 15578006","journal-title":"Neuropsychopharmacology"},{"key":"1867_CR35","doi-asserted-by":"publisher","first-page":"479","DOI":"10.3969\/j.issn.1671-7171.2014.03.022","volume":"31","author":"D Yang","year":"2014","unstructured":"Yang D, Chen J, Chen Y, Peng H. Comparative study of Amisulpride vs .Olanzapine for the treatment of schizophrenia. J Clin Res. 2014;31:479\u2013480,483. \n                    https:\/\/doi.org\/10.3969\/j.issn.1671-7171.2014.03.022\n                    \n                  .","journal-title":"J Clin Res"},{"key":"1867_CR36","doi-asserted-by":"publisher","first-page":"32","DOI":"10.3969\/j.issn.1672-187X.2015.02.011-0032-04","volume":"21","author":"F Yang","year":"2015","unstructured":"Yang F, Zhang C, Wen L. A control study of amisulpride vs olanzapine in the treatment of schizophrenia characterized by negative symptoms. J Clin Psychosom Dis. 2015;21:32\u201334,48. \n                    https:\/\/doi.org\/10.3969\/j.issn.1672-187X.2015.02.011-0032-04\n                    \n                  .","journal-title":"J Clin Psychosom Dis"},{"key":"1867_CR37","doi-asserted-by":"publisher","first-page":"80","DOI":"10.3969\/j.issn.1000-0399.2016.01.026.","volume":"37","author":"K Yao","year":"2016","unstructured":"Yao K, Zhou Q, Sui Y. A comparative study of sulforam and olanzapine on first - episode schizophrenia. Anhui Med J. 2016;37:80\u20132. \n                    https:\/\/doi.org\/10.3969\/j.issn.1000-0399.2016.01.026.","journal-title":"Anhui Med J"},{"key":"1867_CR38","doi-asserted-by":"publisher","first-page":"400","DOI":"10.3969\/j.issn.1009-6574.2014.04.022","volume":"14","author":"J Yi","year":"2014","unstructured":"Yi J, Hu Y, Wan Q. Comparative study on effects of amisulpride and olanzapine on glucose and lipid metabolism in patients with aged schizophrenia. J Neurosci Ment Health. 2014;14:400\u2013402,405. \n                    https:\/\/doi.org\/10.3969\/j.issn.1009-6574.2014.04.022\n                    \n                  .","journal-title":"J Neurosci Ment Health"}],"container-title":["BMC Psychiatry"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12888-018-1867-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s12888-018-1867-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12888-018-1867-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,9,23]],"date-time":"2019-09-23T02:42:33Z","timestamp":1569206553000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcpsychiatry.biomedcentral.com\/articles\/10.1186\/s12888-018-1867-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,9,5]]},"references-count":38,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2018,12]]}},"alternative-id":["1867"],"URL":"https:\/\/doi.org\/10.1186\/s12888-018-1867-8","relation":{},"ISSN":["1471-244X"],"issn-type":[{"value":"1471-244X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,9,5]]},"assertion":[{"value":"15 January 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 August 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 September 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Not applicable.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Chaoyun Li is an employee of Sanofi China. Shuli Qu and Tengbin Xiong are employees of IQVIA China and received research funds from Sanofi China. None of the remaining authors have any personal or financial conflicts of interest.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Publisher\u2019s Note"}}],"article-number":"286"}}